Sensipar patient brochure misleading, US FDA tells Amgen
This article was originally published in Scrip
A patient brochure forAmgen's hyperparathyroidism drug Sensipar (cinacalcet) is false and misleading because it omits and minimises risks and broadens the medicine's indication, the US FDAsaid. The brochure omits the serious risk of adynamic bone disease and the need for monitoring of hepatically impaired patients. The presentation of side- effects information minimises the severity, frequency and duration of nausea and vomiting. The promotion also misleadingly suggests Sensipar is indicated for all patients on dialysis, rather than just those who require treatment for secondary hyperparathyroidism with chronic kidney disease. Amgen said it was working with the FDA to address its concerns and has stopped distributing the brochure.
You may also be interested in...
US FDA received 110 designation requests in July, a high mark that reflects the 60 days needed to review such requests ahead of the 30 September statutory expiration; agency is allowing email submission of RPD and orphan drug designation requests during the COVID-19 pandemic and expects to roll out an online portal for orphan designation requests later this year.
Most vaccines will be distributed centrally by McKesson, but those with ultra-cold storage requirements will be shipped directly from the manufacturer to the vaccination site. Data exchange system will enable public and private databases to talk to each other and help ensure individuals receive timely revaccination with a second dose of the same vaccine regardless of location.
As agency observers wonder whether and how political considerations will impact the timing of a COVID-19 vaccine approval or authorization, the Pink Sheet looks at instances through the years where agency staffers found themselves operating under precedents with which they disagreed or that didn’t work out as expected.